Global drugmakers invest billions to boost U.S. presence

{
  "signal_id": "3e3dd4d6-86ba-77c3-d74a-0bb11be9d69f",
  "signal_type": "news",
  "signal_subtype": "invests_into_assets",
  "detected_at": "2026-08-10T13:27:21+00:00",
  "company": {
    "name": "Pfizer",
    "domain": "pfizer.com"
  },
  "data": {
    "url": "https://www.bnnbloomberg.ca/business/2026/08/10/global-drugmakers-invest-billions-to-boost-us-presence/",
    "title": "Global drugmakers invest billions to boost U.S. presence - BNN Bloomberg",
    "assets": "research and development and domestic manufacturing",
    "excerpt": "Global drugmakers are expanding their U.S. footprint, pledging billions of dollars to ramp up manufacturing capacity and research in the country. Pharmaceutical companies including Eli Lilly, Pfizer, AstraZeneca and Roche have announced roughly US$500 billion in U.S. investments as they seek to strengthen infrastructure, mitigate supply-chain risks and reassure investors. Pfizer PFE.N Pfizer reached a deal with President Donald Trump on September 30 to invest US$70 billion in research and development and domestic manufacturing, and received a three-year grace period exempting its products from the pharmaceutical-targeted tariffs. GSK GSK.L The London-based drugmaker plans to invest US$30 billion in U.S. research and development and supply chain infrastructure over five years. Eli Lilly LLY.N U.S. President Donald Trump said in January that Eli Lilly plans to build six plants in the United States. Lilly said last year that it planned to spend at least US$27 billion to build four U.S. plants to expand production and bolster medical supply chains. The company has since announced details on three plants, in Alabama, Virginia and Texas. Lilly in January said it will build a US$3.5 billion pharmaceutical manufacturing facility in Pennsylvania, its fourth new site, in an effort to expand U.S. production and bolster medical supply chains. Johnson & Johnson JNJ.N The drugmaker plans to...",
    "summary": "Pfizer reached a deal to invest US$70 billion in research and development and domestic manufacturing in the United States.",
    "location": "United States",
    "planning": true,
    "image_url": "https://www.bnnbloomberg.ca/resizer/v2/UV5MM2UGTF3ZHNSGIIFPAFBS4E.jpg?smart=true&auth=e9c7c41df02858bf90cf94caace8572ac7beefc35f4fc347e88da884365d6159&width=1200&height=630",
    "confidence": 0.9,
    "assets_tags": [
      "research_and_development",
      "production"
    ],
    "published_at": "2026-08-10T13:27:21Z",
    "location_data": [
      {
        "region": "Northern America",
        "country": "United States",
        "continent": "Americas",
        "fuzzy_match": false
      }
    ],
    "article_sentence": "Pfizer PFE.N Pfizer reached a deal with President Donald Trump on September 30 to invest US$70 billion in research and development and domestic manufacturing, and received a three-year grace period exempting its products from the pharmaceutical-targeted tariffs.",
    "amount_normalized": 70000000000
  }
}

curl https://signals.autobound.ai/v1/signals/3e3dd4d6-86ba-77c3-d74a-0bb11be9d69f \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"pfizer.com","limit":20}'